Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors

OBJECTIVE: The aim of this study was to determine the rate of coronavirus disease‐19 (COVID‐19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). MATERIALS AND METHODS: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Klebanov, Nikolai, Pahalyants, Vartan, Murphy, William S., Theodosakis, Nicholas, Zubiri, Leyre, Klevens, R. Monina, Kwatra, Shawn G., Lilly, Evelyn, Reynolds, Kerry L., Semenov, Yevgeniy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100539/
https://www.ncbi.nlm.nih.gov/pubmed/33783099
http://dx.doi.org/10.1002/onco.13768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100539/
https://www.ncbi.nlm.nih.gov/pubmed/33783099
http://dx.doi.org/10.1002/onco.13768

Ejemplares similares